Prophylaxis entails long-term continuous intravenous administration of concentrates of the deficient factor with a view to preventing spontaneous bleeds and the development of hemophilic arthropathy. Initiation of prophylaxis at an early age and continuous uninterrupted factor administration in patients with hemophilia have been hailed as essential by such organizations.
The most widely used prophylaxis regimens include the Swedish (Malmö), the Dutch and the Canadian protocols. Different international groups have hailed prophylaxis as the most effective treatment in patients with hemophilia.
Prophylaxis is effectiveness in preventing bleeding and arthropathy in children with (particularly early-onset) hemophilia. Although some retrospective trials confirm the benefits of prophylaxis, others point to a lack of conclusive data to support switching adult patients with established hemophilic arthropathy who always received on-demand treatment to prophylactic treatment.
The potential effects of prophylaxis on the patients’ sex lives, renal status, prostate involvement and cataract must be analyzed before indicating prophylactic treatment in elderly patients.
The high efficacy of prophylactic treatment in patients with hemophilia and inhibitors has been widely reported in the literature.
aReal Fundación Victoria Eugenia
bDepartment of Physiotherapy, Universidad Europea de Madrid
cFishemo CEE, Spanish Hemophilia Federation, Madrid, Spain
Correspondence to Rubén Cuesta-Barriuso, PhD, Real Fundación Victoria Eugenia. 28029, Madrid, Spain. E-mail: firstname.lastname@example.org
Received 10 October, 2018
Accepted 23 October, 2018